Lys-MDMA

Lys-MDMA
Clinical data
Other namesLysine-MDMA; N-(L-Lysinamidyl)-3,4-methylenedioxymethamphetamine; N-(L-Lysinamidyl)-MDMA; lysMDMA
Drug classSerotonin–norepinephrine–dopamine releasing agent; Entactogen; Empathogen
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-N-methylhexanamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC17H27N3O3
Molar mass321.421 g·mol−1
3D model (JSmol)
  • CC(CC1=CC2=C(C=C1)OCO2)N(C)C(=O)[C@H](CCCCN)N
  • InChI=1S/C17H27N3O3/c1-12(20(2)17(21)14(19)5-3-4-8-18)9-13-6-7-15-16(10-13)23-11-22-15/h6-7,10,12,14H,3-5,8-9,11,18-19H2,1-2H3/t12?,14-/m0/s1
  • Key:MJBFXZNNDCEDME-PYMCNQPYSA-N

Lys-MDMA, or lysine-MDMA, also known as N-(L-lysinamidyl)-MDMA, is a prodrug of MDMA which is being investigated for possible use as a pharmaceutical drug in the treatment of psychiatric disorders. Structurally, lys-MDMA is to MDMA as lisdexamfetamine is to dextroamphetamine As of August 2024, a phase 1 clinical trial comparing MDMA, MDA, lys-MDMA, and lys-MDA has been conducted and completed. Lys-MDMA is being developed by MindMed.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.